Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Other Non-Current Liabilities (2019 - 2025)

Immunocore Holdings' Other Non-Current Liabilities history spans 3 years, with the latest figure at $96.6 million for Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities rose 3113.71% year-over-year to $96.6 million; the TTM value through Sep 2025 reached $96.6 million, up 3113.71%, while the annual FY2023 figure was $978000.0, N/A changed from the prior year.
  • Other Non-Current Liabilities for Q3 2025 was $96.6 million at Immunocore Holdings, up from $84.0 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $96.6 million in Q3 2025 and bottomed at $978000.0 in Q4 2023.
  • The 3-year median for Other Non-Current Liabilities is $3.0 million (2024), against an average of $35.9 million.
  • The largest YoY upside for Other Non-Current Liabilities was 3919.15% in 2025 against a maximum downside of 2789.73% in 2025.
  • A 3-year view of Other Non-Current Liabilities shows it stood at $978000.0 in 2023, then skyrocketed by 207.36% to $3.0 million in 2024, then surged by 3113.71% to $96.6 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Other Non-Current Liabilities are $96.6 million (Q3 2025), $84.0 million (Q2 2025), and $62.5 million (Q1 2025).